Skip to contentSkip to filters

We use cookies for analytics.

Podcast

The Genetics Podcast

  • 2 episodes
  • Latest episode Oct 29, 2026
Related content

Topics

Recent episodes

Sek Kathiresan, chief executive of Verve Therapeutics and head of obesity research and early development at Eli Lilly, explains how protective genetic variants led to a one-time in vivo gene-editing therapy for heart disease despite early doubts. He discusses the biological, technological, regulatory and commercial risks, the phase 1 results for Verve-102 and the case for lifelong LDL lowering given cumulative exposure, what recent failures of genetically validated targets and the Lp(a) trial leave unanswered, who benefits most according to polygenic risk scores, and whether one-time gene therapy could work for obesity.

Published Oct 29, 2026 · 36 min

James Zou, associate professor of biomedical data science at Stanford University, describes a virtual biotech staffed by collaborating AI scientist agents that link single-cell evidence behind drug targets to clinical-trial success, how autonomous those agents are, and why missing proprietary trial data is the next gap. He discusses scaling the number of collaborating agents and how teamwork and structure emerged among them, Paper to Agent, which turns published papers into interactive virtual authors and has exposed reproducibility problems across more than 100 papers, and clinical AI from the FDA-cleared EchoNet cardiac-ultrasound tool to SleepFM, which predicts risk of more than 100 diseases from one night of sleep.

Published Oct 15, 2026 · 36 min